Prevention of sudden death in patients with coronary artery disease: Do lipid-lowering drugs play a role?

Preventive Cardiology

Volumn 5, Issue 4, 2002, Pages 177-182

  De Sutter, Johan ^a   Firsovaite, Vida ^a   Tavernier, Rene ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; REVIEW; SUDDEN DEATH; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0036752862     PISSN: 1520037X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1520.037X.2002.00731.x     Document Type: Review

References (60)

1. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation. 1998;98:2334-2351.
2. Mehta D, Curwin J, Gomes JA, et al. Sudden death in coronary artery disease: Acute ischemia versus myocardial substrate. Circulation. 1997;96:3215-3223.
3. The Scandinavian Simvastatin Survival Study Group. Randomised trial for cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
5. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
6. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
7. Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615-1622.
8. Garan H, McComb JM, Ruskin JN. Spontaneous and electrically induced ventricular arrhythmias during acute ischemia superimposed on 2 week old canine myocardial infarction. J Am Coll Cardiol. 1988;11:603-611.
9. Furukawa T, Moroe K, Mayrovitz HN, et al. Arrhythmogenic effects of graded coronary blood flow reductions superimposed on prior myocardial infarction in dogs. Circulation. 1991; 84:368-377.
10. Cinca J, Blanch P, Carenno A, et al. Acute ischemic ventricular arrhythmias in pigs with healed myocardial infarction: Comparative effects of ischemia at a distance and ischemia at the border zone. Circulation. 1997;96:653-658.
11. Cobb LA, Baum RS, Alvarez H 3rd, et al. Resuscitation from out-of-hospital ventricular fibrillation: 4 Years follow-up. Circulation. 1975;52(suppl III)::S223-S235.
12. Goldstein S, Landis JR, Leighton R, et al. Predictive survival models for resuscitated victims of out-of-hospital cardiac arrest with coronary artery disease. Circulation. 1985;71:873-880.
13. The AVID investigators. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. 1999;34:1552-1559.
14. Gomes JAC, Alexopoulous D, Winters SL, et al. The role of silent ischemia, the arrhythmic substrate and the short-long sequence in the genesis of sudden death. J Am Coll Cardiol. 1989;14:1618-1625.
15. De Sutter J, Tavernier R, Van de Wiele C, et al. Infarct size and recurrence of ventricular arrhythmias after defibrillator implantation. Eur J Nucl Med. 2000;27:807-815.
16. Gioia G, Bagheri B, Gottlieb CD, et al. Prediction of outcome of patients with life-threatening ventricular arrhythmias treated with automatic implantable cardioverter defibrillators using SPECT perfusion imaging. Circulation. 1997;95:390-394.
17. Brugada J, Aguinaga L, Mont L, et al. Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: Effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol. 2001;37:529-533.
18. Hohnloser SH. Prevention of recurrent life-threatening arrhythmias: Will lipid-lowering therapy make a difference? J Am Coll Cardiol. 2000;36:773-775.
19. Cao JM, Fishbein MC, Han JB, et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation. 2000;101:1960-1969.
20. Matsunari I, Schricke U, Bengel FM, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation. 2000;101:2579-2585.
21. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988;260(14):2088-2093.
22. Gottlieb S, McCarter R, Vogel R. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-497.
23. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet. 1999;353:9-13.
24. The MERIT-HF Study Group: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
25. Levine JH, Mellits ED, Baumgardner RA, et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation. 1991;84:558-566.
26. Seidl K, Hauer B, Schwick NG, et al. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. Am J Cardiol. 1998;82:744-748.
27. Leclercq JF, Leenhardt A, Coumel P, et al. Efficacy of β-blocking agents in reducing the number of shocks in patients implanted with first-generation automatic defibrillator. Eur Heart J. 1992;13:1180-1184.
28. De Sutter J, Kazmierckzak J, Fonteyne W, et al. Factors determining long-term outcomes and survival in patients with coronary artery disease and ventricular tachyarrhythmias: A single center experience. Pacing Clin Electrophysiol. 2000;23(pt II):1947-1952.
29. Kennedy HL. Beta blockade, ventricular arrhythmias, and sudden cardiac death. Am J Cardiol. 1997;80:29J-34J.
30. Luketich J, Friehling TD, O'Connor KM, et al. The effect of beta-adrenergic blockade on vulnerability to ventricular fibrillation and inducibility of ventricular arrhythmia in shortand long-term feline infarction models. Am Heart J. 1989;118:265-271.
31. De Ferrari GM, Salvati P, Grossoni M, et al. Pharmacological modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed MI. J Am Coll Cardiol. 1993;21:283-290.
32. Holmes D, Davis K, Mock M, et al., for the Participants in the Coronary Artery Surgery Study. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: A report from the Coronary Artery Surgery Study. Circulation. 1986;73:1254-1263.
33. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563-570.
34. Kelly P, Ruskin JN, Vlahakes GJ, et al. Surgical coronary revascularization in survivors of prehospital cardiac arrest: Its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol. 1990;15:267-273.
35. Berntsen RF, Gunnes P, Lie M, et al. Surgical revascularization in the treatment of ventricular tachycardia and fibrillation exposed by exercise-induced ischemia. Eur Heart J. 1993;14:1297-1303.
36. Autschbach R, Falk V, Gonska BD, et al. The effect of coronary artery bypass graft surgery for the prevention of sudden cardiac death: Recurrent episodes after ICD implantation and review of literature. Pacing Clin Electrophysiol. 1994;17(part II):552-558.
37. Daoud EG, Niebauer M, Kou WH, et al. Incidence of implantable defibrillator discharges after coronary revascularization in survivors of ischemic sudden cardiac death. Am Heart J. 1995;130:277-280.
38. Lessmeier TJ, Lehmann MH, Steinman RT, et al. Implantable cardioverter-defibrillator therapy in 300 patients with coronary artery disease presenting exclusively with ventricular fibrillation. Am Heart J. 1994;128:211-215.
39. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded? Circulation. 1989;79:441-444.
40. Sadanandan S, Hochman JS. Early reperfusion, late reperfusion and the open artery hypothesis: An overview. Prog Cardiovasc Disease. 2000;42:397-404.
41. Brugada P, De Swart H, Smeets JLRM, et al. The role of collateral blood supply in ventricular tachycardia after myocardial infarction. Eur Heart J. 1988;9:1104-1111.
42. Carnendran L, Steinberg JS. Does an open infarct-related artery after myocardial infarction improve electrical stability? Prog Cardiovasc Disease. 2000;42(6):439-454
43. Steinberg JS, Gaur A, Sciacca R, et al. New-onset sustained ventricular tachycardia after cardiac surgery. Circulation. 1999;99:903-908.
44. Marchioli R, Marfisi RM, Carinci F, et al. Meta-analysis, clinical trials and transferability of research into practice: The case of cholesterol-lowering intervention in the secondary prevention of coronary heart disease. Arch Intern Med. 1990;156:1158-1172.
45. Moss AJ, Hall WJ, Cannon DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335(26):1933-1940.
46. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337: 1576-1583.
47. Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med. 1997;337: 1569-1575.
48. Pacifico A, Hohnloser S, Williams S, et al., for the d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med. 1999;340:1855-1862.
49. Buxton AE, Lee KL, Fisher JD, et al., for the Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882-1890.
50. Connoly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000; 101:1297-1302.
51. Kuck KH, Cappato R, Siebels J, et al., for the CASH investigators. A randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;120:748-754.
52. De Sutter J, Tavernier R, De Buyzere M, et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol. 2000;36:766-772.
53. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-453.
54. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-213.
55. Rosenson R, Tangney C. Antiatherothrombotic properties of statins. JAMA. 1998;279:1643-1650.
56. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary artery disease. Circulation. 1997;95:324-328.
57. Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation. 1999;99: 3227-3233.
58. Schwartz GG, Oliver MF, Ezekowitz MD, et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol. 1998;8:578-581.
59. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators. Nature. 1998;393:790-793.
60. Kockx M, Gervois PP, Poulain P, et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood. 1999;93:2991-2998.